Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study

BACKGROUND: Reduced MS disease activity with alemtuzumab versus subcutaneous interferon beta-1a (SC IFNB-1a) in core phase 2/3 studies was accompanied by increased incidence of infections that were mainly nonserious and responsive to treatment. Alemtuzumab efficacy was durable over 6 years. OBJECTIV...

Descripción completa

Detalles Bibliográficos
Autores principales: Wray, Sibyl, Havrdova, Eva, Snydman, David R, Arnold, Douglas L, Cohen, Jeffrey A, Coles, Alasdair J, Hartung, Hans-Peter, Selmaj, Krzysztof W, Weiner, Howard L, Daizadeh, Nadia, Margolin, David H, Chirieac, Madalina C, Compston, D Alastair S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764150/
https://www.ncbi.nlm.nih.gov/pubmed/30289355
http://dx.doi.org/10.1177/1352458518796675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764150/
https://www.ncbi.nlm.nih.gov/pubmed/30289355
http://dx.doi.org/10.1177/1352458518796675

Ejemplares similares